Jump to Content
Jump to Main Navigation
User Account
Sign In
to save searches and organize your favorite content.
Not registered?
Sign up
My Content
(0)
Searches
(0)
More
Subscriptions
Join E-mail List
Help
JNCCN
Menu
Home
Content
Current Issue
Past Issues
Online First
Supplements
NCCN Meeting Highlights
JNCCN In the News
COVID-19
CE
JNCCN 360
Author Center
Call for Papers
Submit a Manuscript
Information for Authors
Reprints/Permissions
About
JNCCN
Editorial Board
Editorial Calendar
NCCN
Harborside
Search
Close
Advanced Search
Help
HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018
Authors:
Weijia Wang
MSc
,
Edward Li
PharmD, MPH
1
,
Kim Campbell
PharmD, BCOP
1
and
Ali McBride
PharmD, MS, BCOP, FAzPA, FASHP
2
,
3
View More
View Less
1
Sandoz Inc., Princeton, NJ
2
Banner University Medical Center, Tucson, AZ
3
University of Arizona Cancer Center, Tucson, AZ
Volume/Issue:
Volume 19: Issue 3.5
Online Publication Date:
17 Mar 2021
DOI:
https://doi.org/10.6004/jnccn.2020.7718
Restricted access
Purchase article (
USD
$0.01
)
Citation Alert
Get Permissions
Article Details
Corresponding Author: Weijia Wang, MSc
Print
Collapse
Expand
Top
Article Information
Copyright:
Copyright © 2021 by the National Comprehensive Cancer Network 2021
Page Numbers:
HSR21-073
Article Category:
Abstract
Print Publication Date:
20 Mar 2021
Online Publication Date:
17 Mar 2021
Citation Alert
Get Permissions
PubMed
Article by Weijia Wang
Article by Edward Li
Article by Kim Campbell
Article by Ali McBride
Google Scholar
Article by Weijia Wang
Article by Edward Li
Article by Kim Campbell
Article by Ali McBride
Similar articles in Google Scholar
Related Articles
Metrics
All Time
Past Year
Past 30 Days
Abstract Views
0
0
0
Full Text Views
97
97
59
PDF Downloads
160
160
63
EPUB Downloads
0
0
0
[18.206.177.17]
18.206.177.17
Sign in to annotate
Close
Edit
Character limit
500
/500
Delete
Cancel
Save
@!
Character limit
500
/500
Cancel
Save